Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Vasc Endovascular Surg. 2023 Aug;57(6):583-591. doi: 10.1177/15385744231162941. Epub 2023 Mar 7.
This study aims to evaluate the use of prophylactic intravenous hydration (IV prophylaxis) and carbon dioxide (CO) angiography in reducing contrast associated-acute kidney injury (CA-AKI) and determine the overall incidence and risk factors of CA-AKI in high-risk patients undergoing peripheral vascular interventions (PVI). Only patients undergoing elective PVI from 2017 to 2021 with chronic kidney disease (CKD) stage 3-5 in the Vascular Quality Initiative (VQI) database were included. Patients were grouped into IV prophylaxis vs no prophylaxis. The study's primary outcome was CA-AKI, defined as a rise in creatinine (>.5 mg/dL) or new dialysis within 48 hours following contrast administration. Standard univariate and multivariable (logistic regression) analyses were conducted. A total of 4497 patients were identified. Of these, 65% received IV prophylaxis. The overall incidence of CA-AKI was .93%. No significant difference was seen in overall contrast volume (mean (SD): 66.89(49.54) vs 65.94(51.97) milliliters, > .05) between the 2 groups. After adjusting for significant covariates, the use of IV prophylaxis (OR (95% CI): 1.54(.77-3.18), = .25) and CO angiography (OR (95%CI): .95(.44-2.08), = .90) was not associated with a significant reduction in CA-AKI compared to the patients with no prophylaxis. The severity of CKD and diabetes were the only predictor of CA-AKI. Compared to patients with no CA-AKI, patients with CA-AKI were at risk of higher 30-day mortality (OR (95% CI): 11.09 (4.25-28.93)) and cardiopulmonary complications (OR (95% CI): 19.03 (8.74-41.39) following PVI (Both < .001). Using a large national vascular database, our study demonstrates that prophylactic use of IV hydration and CO angiography in high-risk CKD patients is not associated with a reduction in renal injury following PVI. Reduced kidney function and history of diabetes is an independent predictor of CA-AKI and patients that develop post-procedural AKI are at an increased risk of morbidity and mortality.
本研究旨在评估预防性静脉补液(IV 预防)和二氧化碳(CO)血管造影在降低对比相关急性肾损伤(CA-AKI)中的作用,并确定在血管质量倡议(VQI)数据库中接受外周血管介入(PVI)的高危患者中 CA-AKI 的总体发生率和危险因素。 仅包括 2017 年至 2021 年期间患有慢性肾脏病(CKD)3-5 期的 VQI 数据库中接受选择性 PVI 的患者。将患者分为 IV 预防组和无预防组。该研究的主要结局是 CA-AKI,定义为在造影剂给药后 48 小时内肌酐升高(>.5mg/dL)或新透析。进行了标准的单变量和多变量(逻辑回归)分析。 共确定了 4497 名患者。其中,65%接受了 IV 预防。CA-AKI 的总体发生率为 0.93%。两组之间的总体造影剂体积(平均值(SD):66.89(49.54)与 65.94(51.97)毫升, >.05)无显著差异。在调整了显著协变量后,与无预防组相比,使用 IV 预防(OR(95%CI):1.54(.77-3.18), =.25)和 CO 血管造影(OR(95%CI):.95(.44-2.08), =.90)并没有显著降低 CA-AKI 的发生率。CKD 严重程度和糖尿病是 CA-AKI 的唯一预测因素。与无 CA-AKI 的患者相比,有 CA-AKI 的患者在接受 PVI 后 30 天死亡风险更高(OR(95%CI):11.09(4.25-28.93))和心肺并发症风险更高(OR(95%CI):19.03(8.74-41.39))(均 <.001)。 使用大型国家血管数据库,我们的研究表明,在高危 CKD 患者中预防性使用 IV 水化和 CO 血管造影并不会降低 PVI 后肾损伤的发生率。肾功能下降和糖尿病史是 CA-AKI 的独立预测因素,发生术后 AKI 的患者发病率和死亡率增加。